Clinical Trial Update: A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating CC-486/Onureg in participants with hepatic impairment versus normal hepatic function in myeloid malignancies has been terminated. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Malignancies

Drugs mentioned

• Onureg (azacitidine)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatic Insufficiency, Neoplasms | Phase 1 | Status: TERMINATED